Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Medtronic
Moodys
Mallinckrodt
Colorcon
Johnson and Johnson

Last Updated: December 3, 2022

CLINICAL TRIALS PROFILE FOR LOTEMAX SM


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Lotemax Sm

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00366691 ↗ Comparison of Acular LS With Lotemax to Prevent Inflammation After Cataract Surgery and Intraocular Lens Implantation Completed Medical University of South Carolina Phase 4 2006-02-01 The purpose of this study is to compare the effectiveness of Acular LS® and Lotemax® in the prevention of inflammation in the eye after cataract surgery. Acular LS is made by Allergan, Inc. It is a nonsteroidal anti-inflammatory drug (NSAID) and is approved by the Food and Drug Administration (FDA) for use following cataract surgery. Lotemax is made by Bausch & Lomb. It is a steroid and is also approved by the FDA for use following cataract surgery.
NCT00407043 ↗ Multicenter, Randomized, Controlled Study of the Effect of Lotemax on Initiation of Dry Eye Treatment With Restasis Completed Bausch & Lomb Incorporated Phase 4 2006-11-01 To evaluate the impact of Lotemax on the initiation of Restasis therapy in patients with dry eye. It is hypothesized that the anti-inflammatory activity of Lotemax may help mitigate the stinging with cyclosporine administration and the dry eye signs and symptoms experienced during the initiation of therapy.
NCT00407043 ↗ Multicenter, Randomized, Controlled Study of the Effect of Lotemax on Initiation of Dry Eye Treatment With Restasis Completed Ophthalmic Consultants of Long Island Phase 4 2006-11-01 To evaluate the impact of Lotemax on the initiation of Restasis therapy in patients with dry eye. It is hypothesized that the anti-inflammatory activity of Lotemax may help mitigate the stinging with cyclosporine administration and the dry eye signs and symptoms experienced during the initiation of therapy.
NCT00560638 ↗ Loteprednol Etabonate Opthalmic Suspension for the Treatment of Dry Eye Completed Bausch & Lomb Incorporated Phase 2 2005-11-01 This was a single-center, randomized, double-masked, placebo-controlled, parallel-group, 4-visit, CAE (Controlled Adverse Environment) study lasting approximately 4 weeks. Subjects were randomized to receive loteprednol etabonate ophthalmic suspension, 0.5% or placebo (vehicle of loteprednol etabonate ophthalmic suspension, 0.5%) and instructed to dose bilaterally either TID or QID according to randomization.
NCT00705159 ↗ Safety and Efficacy of Zylet vs Lotemax, Tobramycin and Vehicle in Pediatric Blepharoconjunctivitis Completed Bausch & Lomb Incorporated Phase 4 2008-06-01 The objective of this study is to evaluate the safety and effectiveness of Zylet in comparison with Lotemax, Tobramycin and the vehicle of Zylet for the treatment of blepharoconjunctivitis in pediatric subjects.
NCT00781300 ↗ Intraocular Pressure With Loteprednol and Dexamethasone Completed Federal University of São Paulo Phase 4 2006-03-01 The purpose of this study is to compare intraocular pressure (IOP) changes after pterygium surgery among patients using loteprednol and dexamethasone during the postoperative period.
NCT01193504 ↗ Randomized, Masked Comparison of Bromfenac and Besifloxacin BID With Either Prednisolone BID or Loteprednol 0.5% BID for Prevention of Retinal Thickening and CME Following Phacoemulsification Unknown status Innovative Medical Phase 4 2010-09-01 The purpose of this study is to determine if Lotemax eye drops are at least as effective as Pred Forte eye drops, which are the standard of care after cataract surgery.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Lotemax Sm

Condition Name

Condition Name for Lotemax Sm
Intervention Trials
Inflammation 4
Dry Eye Disease 4
Dry Eye 3
Pain 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Lotemax Sm
Intervention Trials
Dry Eye Syndromes 8
Keratoconjunctivitis Sicca 7
Inflammation 6
Cataract 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Lotemax Sm

Trials by Country

Trials by Country for Lotemax Sm
Location Trials
United States 19
Brazil 1
Israel 1
Korea, Republic of 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Lotemax Sm
Location Trials
Massachusetts 5
New York 3
New Jersey 2
California 2
Ohio 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Lotemax Sm

Clinical Trial Phase

Clinical Trial Phase for Lotemax Sm
Clinical Trial Phase Trials
Phase 4 12
Phase 3 2
Phase 2 2
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Lotemax Sm
Clinical Trial Phase Trials
Completed 16
Unknown status 3
Recruiting 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Lotemax Sm

Sponsor Name

Sponsor Name for Lotemax Sm
Sponsor Trials
Bausch & Lomb Incorporated 11
Massachusetts Eye and Ear Infirmary 3
Tufts Medical Center 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Lotemax Sm
Sponsor Trials
Other 18
Industry 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
McKinsey
Medtronic
Boehringer Ingelheim
Merck
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.